Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People
Portfolio Pulse from Vandana Singh
Virios Therapeutics Inc announced that its combination therapy of valacyclovir and celecoxib showed significant improvements in patients with Long-COVID. The company plans to meet with the FDA in 2023 to discuss an investigational new drug application. Despite the positive news, VIRI shares are down 21.10%.
July 17, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite positive news about its Long-COVID therapy, Virios Therapeutics' shares are down 21.10%.
The news about the successful Long-COVID therapy should have been positive for the company. However, the stock price has fallen significantly, indicating that other factors may be influencing the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100